Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study
- 22 April 2026
- journal article
- research article
- Published by Elsevier in The Lancet Rheumatology
- Vol. 8 (7) , e550-e562
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30 AR072577)
This publication has 36 references indexed in Scilit:
- Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort studyClinical and Experimental Medicine, 2024
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- Persistence and Safety of Golimumab in Elderly Patients with Rheumatoid Arthritis and Renal Dysfunction in a Real-World SettingDrugs - Real World Outcomes, 2022
- The prevalence of pain among patients with chronic kidney disease using systematic review and meta-analysisKidney International, 2021
- Developmental stages of tertiary lymphoid tissue reflect local injury and inflammation in mouse and human kidneysKidney International, 2020
- Overlap WeightingJAMA, 2020
- Disease Activity in Rheumatoid Arthritis and the Risk of Cardiovascular EventsArthritis & Rheumatology, 2015
- Skin Denervation and Its Clinical Significance in Late-Stage Chronic Kidney DiseaseArchives of Neurology, 2011
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009